Adult congenital heart care in the COVID-19 era, and beyond: A call for action

Michael A Gatzoulis1,2,3, Natali Chung1,3, Paolo Ferrero4

  • 1Adult Congenital Heart Centre and National Centre for Pulmonary Arterial Hypertension, Royal Brompton & Harefield NHS Trust, National Heart & Lung Institute, Imperial College, London, UK.

Insights

The COVID-19 pandemic necessitates enhanced support for adult congenital heart disease (ACHD) patients, advocating for improved care models and patient experiences post-pandemic.

Area of Science:

  • Cardiology
  • Public Health
  • Infectious Diseases

Background:

  • The COVID-19 pandemic presents unprecedented global challenges.
  • The pandemic significantly impacts not only health but also economic and psychosocial well-being.
  • Vulnerable populations, including the elderly and disabled, require special attention.

Purpose of the Study:

  • To outline a call for action to support and protect adult congenital heart disease (ACHD) patients during the COVID-19 crisis.
  • To propose a vision for an improved model of ACHD care for the post-pandemic era.
  • To emphasize the broader applicability of discussed principles beyond ACHD patients.

Main Methods:

  • This viewpoint article presents a strategic call to action.
  • It synthesizes current challenges and proposes future healthcare improvements.
  • The approach involves a global perspective on patient care and societal well-being.

Main Results:

  • The pandemic highlights the need for robust support systems for vulnerable patient groups.
  • A revised model of ACHD care is proposed to enhance patient journeys and healthcare experiences.
  • The article stresses the importance of self-care and collective well-being during crises.

Conclusions:

  • The COVID-19 pandemic underscores the need for adaptive and improved healthcare models, particularly for ACHD patients.
  • The proposed changes aim to create a better life journey and healthcare experience for ACHD patients.
  • The principles discussed have wide-ranging implications for public health and societal care, emphasizing inclusivity and self-reflection.

Related Concept Videos

Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.5K
Development of the Heart01:27

Development of the Heart

The development of the human heart, a crucial organ, commences from the mesoderm on the 18th or 19th day after fertilization. This process initiates in the cardiogenic area, a group of mesodermal cells at the embryo's head end, which evolves into elongated strands known as cardiogenic cords. These cords undergo a transformation to form hollow-centered endocardial tubes.
As the embryo undergoes lateral folding, these paired tubes approach each other, merging into a single primitive heart...
929
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
205
Acute Respiratory Failure-I01:21

Acute Respiratory Failure-I

Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
204
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
218
Acute Respiratory Failure-III01:30

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
184